LSKL, Inhibitor of Thrombospondin TSP-1是 TGF-β 的激活剂。

LSKL, Inhibitor of Thrombospondin TSP-1 acetate is activation of TGF-β .

Administration of LSKL peptide attenuated Smad2 phosphorylation at 6 h. S-phase entry of hepatocytes was accelerated at 24 and 48 h by LSKL peptide, which resulted in faster recovery of the residual liver and bodyweight.?Haematoxylin and eosin tissue staining and blood biochemical examinations revealed no significant adverse effects following the two LSKL peptide administrations.?In the clinical setting, plasma TSP-1 levels were lowest on the first day after hepatectomy.?However, plasma TSP-1 levels at this stage were significantly higher in patients with subsequent liver dysfunction compared with levels in those without liver dysfunction following hepatectomy

Mice were operated on with a 70 per cent hepatectomy or sham procedure. Operated mice received either LSKL peptide or normal saline intraperitoneally at abdominal closure and 6 h after hepatectomy. Perioperative plasma TSP-1 levels were measured by enzyme-linked immunosorbent assay in patients undergoing hepatectomy.

T7676

C25H44F6N6O9

686.64

LSKL, Inhibitor of Thrombospondin TSP-1

DMSO:10 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years